ARCTURUS THERAPEUTICS INC.

Company Overview

Arcturus Therapeutics is a global company making medicines that target the infectious disease, vaccines, and significant opportunities within liver and respiratory rare diseases. It is a late-stage messenger RNA-based therapeutics company. It utilizes lipid mediated drug delivery system for mRNAi therapeutics. Arcturus was a preclinical stage company at the end of 2020, and by September 2021, it became a late-stage clinical company.

Arcturus Therapeutics has a patented delivery system called Lunar. The company is currently focusing on two pipelines: LUNAR-OTC and LUNAR-CF. They are focused on ornithine transcarbamylase (OTC) deficiency and cystic fibrosis, respectively.

The company has a technology called STARR, which along with LUNAR technology, forms a nanoparticle delivery system. Once the molecule has been delivered into the cell, it generates a protective immune response or drives therapeutic protein expression to potentially prevent or treat various diseases.

Financial Highlights (FY 2024)

Company's Business Segments

• RNA Therapeutics : The company offers late-stage RNA and mRNA rare therapeutics and vaccines for the treatment of rare diseases such as ornithine transcarbamylase deficiency and respiratory diseases.